Table 2.
Characteristics of patients who discontinued radiotherapy
| No | Age (years)/Gender | Smoking history (pack-years) | Pathological type/Tumor stage | Treatment modality | Induction chemotherapy regimen | Radiotherapy dose (Gy/fraction) | Percentage of lung volume affected in subclinical ILD (%) | Grade of RP |
|---|---|---|---|---|---|---|---|---|
| 1 | 68/Male | 40 | Squamous cell carcinoma/IIIB | RT | Cisplatin + gemcitabine | 44.0/22 | ≥ 25 | 4 |
| 2 | 77/Male | 50 | Squamous cell carcinoma/IIIB | RT | Carboplatin + gemcitabine | 49.5/22 | ≥ 25 | 5 |
| 3 | 67/Male | No | Squamous cell carcinoma/postoperative stump recurrence | RT | Cisplatin + gemcitabine | 24.0/12 | < 25 | 2 |
| 4 | 63/Male | 80 | Adenocarcinoma/IIIB | RT | Cisplatin + gemcitabine | 58.0/29 | < 25 | 3 |
| 5 | 65/Male | 40 | NSCLC/IIIB | RT | Cisplatin + vinorelbine | 38.0/19 | < 25 | 4 |
| 6 | 69/Male | 50 | Squamous cell carcinoma/IIIB | RT | Carboplatin + gemcitabine | 38.0/19 | ≥ 25 | 5 |
| 7 | 52/Male | 60 | Adenocarcinoma/IIIB | RT | Cisplatin + pemetrexed | 30.0/15 | < 25 | 2 |
| 8 | 67/Male | No | SCLC/IIIB | RT | Carboplatin + etoposide | 40.0/20 | < 25 | 2 |
RP, radiation pneumonitis; ILD, interstitial lung disease; RT, radiation therapy; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer